1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,394 | 0,474 | 07:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | - | HKEx | ||
| Mi | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 06.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR, FROM THE CHINA CDE | 2 | HKEx | ||
| 04.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | - | HKEx | ||
| 04.03. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 03.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | - | HKEx | ||
| 03.03. | ABBISKO-B (02256): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; (2) CHANGE IN USE OF NET PROCEEDS; (3) INSIDE INFORMATION; AND ... | - | HKEx | ||
| 28.02. | ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 28.02. | ABBISKO-B (02256): (1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION ... | 1 | HKEx | ||
| 17.02. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 20.01. | BRIEF: Abbisko moves into the black in 2024 | 1 | Bamboo Works | ||
| 20.01. | ABBISKO-B (02256): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 20.12.24 | ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.12.24 | ABBISKO-B (02256): RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES | 1 | HKEx | ||
| 16.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL TO INITIATE A REGISTRATIONAL CLINICAL STUDY OF IRPAGRATINIB (ABSK011) IN PATIENTS WITH HCC | 1 | HKEx | ||
| 11.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL STUDY OF ABSK043, AN ORAL PD-L1 SMALL-MOLECULE INHIBITOR, IN COMBINATION ... | 2 | HKEx | ||
| 09.12.24 | 2024 ASH Oral Presentation: Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting | 101 | PR Newswire | SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients... ► Artikel lesen | |
| 06.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ESMO ASIA 2024: ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON UPDATED RESULTS FROM A PHASE I STUDY OF ABSK043, ... | 1 | HKEx | ||
| 03.12.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - U.S. FDA IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR | 1 | HKEx | ||
| 22.11.24 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST-PATIENT DOSED IN GASTRIC CANCER IN PHASE II CLINICAL STUDY EVALUATING ABSK043, AN ORAL PD-L1 INHIBITOR, ... | 2 | HKEx |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 50,23 | 0,00 % | Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal? | ||
| ARCUTIS BIOTHERAPEUTICS | 16,450 | 0,00 % | What's Going On With Arcutis Biotherapeutics Stock Monday? | ||
| SPRINGWORKS THERAPEUTICS | 49,900 | 0,00 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,850 | 0,00 % | Recursion Pharmaceuticals' Options: A Look at What the Big Money is Thinking | ||
| QUANTUM-SI | 1,715 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 33,740 | 0,00 % | Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 | ||
| BEAM THERAPEUTICS | 24,460 | 0,00 % | Citi lifts Beam Therapeutics stock price target to $64 | ||
| EVOTEC | 6,710 | +3,55 % | 100 %-Rally im Anflug? Evotec, D-Wave und KI-Perle NetraMark Aktie | Der Selloff im Tech-Sektor hält auch zum Wochenbeginn an. Ändert sich das Sentiment, könnte eine 100 %-Rally starten. Dies erwarten jedenfalls Analysten bei D-Wave. Insgesamt sehen Analysten den Quantum-Star... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,820 | 0,00 % | Will ADMA Biologics Stock Continue Its Momentum in 2025? | ||
| QIAGEN | 36,670 | +1,06 % | Biotech Report: Evotec und Qiagen wenig bewegt | (shareribs.com) Frankfurt / New York 13.03.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend im Plus. Evotec und Qiagen notieren kaum verändert. Biontech klettern. An der Wall Street... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 18,840 | 0,00 % | Regencell Bioscience Stock Surges 126% | ||
| NUVALENT | 76,56 | 0,00 % | UBS lifts Nuvalent stock rating, maintains $100 price target | ||
| SUMMIT THERAPEUTICS | 20,225 | 0,00 % | Summit Therapeutics issues stock options to new employees | ||
| DYNE THERAPEUTICS | 12,400 | 0,00 % | Dyne: Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement... ► Artikel lesen | |
| BIONTECH | 92,10 | -1,18 % | Umschichtung von USA nach Europa - BioNTech, Evotec, Vidac Pharma | Die Sanktionspolitik der US-Administration unter US-Präsident Donald Trump schlägt sich langsam bei den US-Indizes durch. Seit der Wahl im November 2024 stagniert der Dow Jones auf hohem Niveau, während... ► Artikel lesen |
ABBISKO CAYMAN LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,895 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.
